Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.
IPO Year: 2015
Exchange: NASDAQ
Website: gbt.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2022 | Outperform → Mkt Perform | William Blair | |
| 8/8/2022 | $40.00 → $72.00 | Hold → Buy | Canaccord Genuity |
| 3/28/2022 | $138.00 → $71.00 | Outperform | Wedbush |
| 2/28/2022 | $28.00 → $31.00 | Equal-Weight | Morgan Stanley |
| 2/24/2022 | $92.00 → $86.00 | Outperform | Oppenheimer |
| 12/21/2021 | $56.00 → $53.00 | Outperform | SVB Leerink |
| 12/14/2021 | $54.00 → $56.00 | Outperform | SVB Leerink |
| 12/7/2021 | Market Perform → Outperform | William Blair | |
| 11/5/2021 | $66.00 → $64.00 | Outperform | RBC Capital |
| 10/7/2021 | $68.00 | Buy | Jefferies |
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors. Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership and advocacy in hematology, will serve on the board’s research and development committee. “We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her deep expertise in blood
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of dire
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. “As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace
SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close. Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the e
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company's next-generation sickle hemo
Conference call and webcast will include data presented at EHA 2022 and business and R&D updates Company to also participate in the William Blair and Goldman Sachs investor conferences SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host a conference call and webcast for the investment community on Friday, June 10, 2022, at 3:00 p.m. CEST (9:00 a.m. ET) to discuss data on its sickle cell programs presented at the European Hematology Association (EHA) Annual Congress and to provide business and R&D updates. To participate in the conference call, please dial (877) 407-3982 (domestic) or +1 (201)
Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 years and over Reinitiated GBT601 Phase 1 trial in sickle cell disease (SCD) patients to study 150 mg daily dose; on track to initiate Phase 2/3 trial by mid-year Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported financial results for the first quarter ended March 31, 2022, and recent business progress.
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the eve
Achieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted by pediatric label expansion in the U.S., marketing authorization for ages 12 and over in the EU, and advancement of R&D pipeline Strong balance sheet with cash and investments totaling $734.8 million at year end Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported financial results for the fourth quarter and year ended December 31, 2021, and recent business progress. "2021
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. financial markets close. Management will host a conference call on Wednesday, February 23, 2022, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and to provide a general business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast
GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy volunteers Study results provide proof of concept to support the continued development of GBT601 GBT to host investor conference call and webcast today at 12:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a Phase 1 study of GBT021601 (GBT601), the company's investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor, that demonstrat
Achieved Oxbryta® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target action date of December 25, 2021 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported financial results for the third quarter ended September 30, 2021 and recent business progress. "Our third quarter results reflect progress with our ongoing initiatives to drive Oxbryta awareness, adoption and access, and like others in our industry, this was partially offset by the i
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease (SCD) treatment, research and education. The new legislation is sponsored by Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of New Jersey. The bill would create a national network of SCD treatment centers in which healthcare providers and communit
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Month, is open to the public and will be live streamed on the SCD Therapeutics Conference website and the Facebook page of Sickle Cell Warriors, an SCD community organization. Admiral Rachel Levine, M.D., assistant secretary for health, U.S. Department of Health and Human Services (HHS), will provide remarks at the
NEW YORK, NY / ACCESSWIRE / August 27, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
NEW YORK, NY / ACCESSWIRE / August 20, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Lifshitz Law PLLC:Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request
NEW YORK, NY / ACCESSWIRE / August 13, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
NEW YORK, NY / ACCESSWIRE / August 10, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on August 1, 2022, the compensation committee of GBT's board of directors granted 10 new employees restricted stock units for an aggregate of 30,450 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT's board of direct
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022, at 2:20 p.m. E.T. The fireside chat will be webcast live from GBT's website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event. About Global Blood Therapeutics Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communit
15-12G - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
William Blair downgraded Global Blood Therapeutics from Outperform to Mkt Perform
Canaccord Genuity upgraded Global Blood Therapeutics from Hold to Buy and set a new price target of $72.00 from $40.00 previously
Wedbush resumed coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $71.00 from $138.00 previously
Morgan Stanley reiterated coverage of Global Blood Therapeutics with a rating of Equal-Weight and set a new price target of $31.00 from $28.00 previously
Oppenheimer reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $86.00 from $92.00 previously
SVB Leerink reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $53.00 from $56.00 previously
SVB Leerink reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $56.00 from $54.00 previously
William Blair upgraded Global Blood Therapeutics from Market Perform to Outperform
RBC Capital reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $64.00 from $66.00 previously
Jefferies initiated coverage of Global Blood Therapeutics with a rating of Buy and set a new price target of $68.00
-Reuters
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter. Global Blood Therapeutics collected $55.16 million in revenue during Q1, but reported earnings showed a $81.42 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the futur
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47 million. Global Blood Therapeutics collected $55.16 million in revenue during Q1, but reported earnings showed a $81.42 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings pe
Novo Nordisk A/S (NYSE:NVO) has agreed to acquire Forma Therapeutics Holdings Inc (NASDAQ:FMTX) for $20 per share in cash, representing a total equity value of $1.1 billion. The deal value offers a premium of 92% to Forma Therapeutics' volume-weighted average price per share over the past 30 days. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on treating sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy to complement and accelerate its scientific presence and pipeline in hemoglobinopathies. Last month, Pfizer Inc (NYSE:PFE) a
Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-track regulatory submissions for CTX001 in SCD/BT by YE22 and CTA submission for VCTX211 (next generation) for Type 1 Diabetes (T1D) in 2H22. Though investors are focused on BLA submission for CTX001, the analyst expects a high probability of approval even with some delay. But Barclays has moved to the sidelines, given some questions on the durability of the allogeneic CAR-T programs and the lack of other major data catalysts in the next 12 months. CRSP is downgraded to Equal Weight with a price
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 7 0 0 Last 30D 0 0 5 0 0 1M Ago 1 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 These 8 analysts have an average price target of $64.88 versus the current price of Global Blood Therapeutics at $66.545, implying downside. Below is a summary of how these 8 analysts rated Global Blood Therapeutics over the past 3 months. The greater the number of bullish
Upgrades For Nutrien Ltd (NYSE:NTR), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Nutrien earned $5.85 in the second quarter, compared to $2.08 in the year-ago quarter. The stock has a 52-week-high of $117.25 and a 52-week-low of $67.23. At the end of the last trading period, Nutrien closed at $85.53. Cantor Fitzgerald upgraded the previous rating for Inspirato Incorporated (NASDAQ:ISPO) from Neutral to Overweight. The stock has a 52-week-high of $108.00 and a 52-week-low of $4.00. At the end of the last trading period, Inspirato closed at $4.94. For Restaurant Brands International Inc (NYSE:QSR), Argus Research upgraded the previous rating of Hold
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 7 0 0 Last 30D 0 0 5 0 0 1M Ago 1 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Global Blood Therapeutics. The company has an average price target of $64.88 with a high of $72.00 and a low of $36.00. Below is a summary of how these 8 analysts rated Global Blood Therapeutics over t
RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and raises the price target from $60 to $68.5.
Wells Fargo analyst Jim Birchenough downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Equal-Weight and raises the price target from $66 to $68.5.